Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic
| dc.creator | Detoc, Maëlle | |
| dc.creator | Bruel, Sébastien | |
| dc.creator | Frappe, Paul | |
| dc.creator | Tardy, Bernard | |
| dc.creator | Botelho-Nevers, Elisabeth | |
| dc.creator | Gagneux-Brunon, Amandine | |
| dc.date.accessioned | 2020-10-06T17:44:17Z | |
| dc.date.available | 2020-10-06T17:44:17Z | |
| dc.date.issued | 2020-10 | |
| dc.description.abstract | Introduction The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial. Methods We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial. Results Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4% of the respondents. According to their statements, 2.512 participants (77.6%, 95% CI 76.2–79%) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9–49.3%) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial. Conclusions Nearly 75% and 48% of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake. | pt_BR |
| dc.identifier.citation | DETOC, M. et al. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine, [S.l.], v. 38, n. 45, p. 7002-7006, Oct. 2020. | pt_BR |
| dc.identifier.uri | https://repositorio.ufla.br/handle/1/43325 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0264410X20312019 | pt_BR |
| dc.language | en_US | pt_BR |
| dc.publisher | Elsevier | pt_BR |
| dc.rights | restrictAccess | pt_BR |
| dc.source | Vaccine | pt_BR |
| dc.subject | COVID-19 - Vaccine | pt_BR |
| dc.subject | Vaccine hesitanc | pt_BR |
| dc.subject | Pandemic | pt_BR |
| dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | pt_BR |
| dc.title | Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic | pt_BR |
| dc.type | Artigo | pt_BR |
Arquivos
Licença do pacote
1 - 1 de 1
Carregando...
- Nome:
- license.txt
- Tamanho:
- 953 B
- Formato:
- Item-specific license agreed upon to submission
- Descrição:
